Echinocandins and pneumocandins--a new antifungal class with a novel mode of action
about
In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolatesIn vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp.In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patientsEfficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosisUpdate on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors.Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis.Directed evolution of the nonribosomal peptide synthetase AdmK generates new andrimid derivatives in vivo.Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits.Quantitative analysis of the antifungal drug anidulafungin by LC-online SPE-MS/MS in human plasma.Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.Rationale for combination antifungal therapy.Antifungal drug resistance.Invasive aspergillosis in solid-organ transplantation: report of eight cases and review of the literature.Therapy of systemic fungal infections.Alteramide B is a microtubule antagonist of inhibiting Candida albicans.Safety and potential of drug interactions of caspofungin and voriconazole in multimorbid patients.Host defense antimicrobial peptides as antibiotics: design and application strategies.The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.Antifungal research strategies aiming for new targets.A clinical review of echinocandins in pediatric patients.Anidulafungin: an evidence-based review of its use in invasive fungal infections.Short native antimicrobial peptides and engineered ultrashort lipopeptides: similarities and differences in cell specificities and modes of action.Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes.Pathogenesis of Candida albicans biofilm.40 years of medical mycology at JAC.Antifungal Resistance, Metabolic Routes as Drug Targets, and New Antifungal Agents: An Overview about Endemic Dimorphic Fungi.N-terminal fatty acid substitution increases the leishmanicidal activity of CA(1-7)M(2-9), a cecropin-melittin hybrid peptide.Comparative evaluation of disk diffusion with microdilution assay in susceptibility testing of caspofungin against Aspergillus and Fusarium isolatesNovel Agents and Drug Targets to Meet the Challenges of Resistant Fungi.Heat shock protein 90 localizes to the surface and augments virulence factors of Cryptococcus neoformans.Efficacy of posaconazole in a murine model of central nervous system aspergillosis.Pharmacological agents in development for invasive aspergillosis.QuBiLs-MAS method in early drug discovery and rational drug identification of antifungal agents.Antimicrobial activity and membrane selective interactions of a synthetic lipopeptide MSI-843Lack of pharmacokinetic interaction between anidulafungin and tacrolimus.Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients?Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine.New agents for the treatment of systemic fungal infections--current status.
P2860
Q28345261-7C2E3D84-A03A-48DD-BB82-45ECB32D4EC1Q28369044-BC9627E0-A9A5-42AA-AD84-F7D6A8A09C44Q28376042-C98F7643-B86A-485D-BF8E-6B639EB85536Q28379470-7B73C0D1-7E7C-440E-ADE4-25A033D2B4CCQ31936121-D594A908-006C-4E50-9291-4E2364554B89Q33805542-3CF779C6-48CE-4CB4-8431-BA8B34EE1FA7Q33910739-BCA0F967-9C4F-4D79-A7F8-0B8243148F55Q33983506-39DE5762-4689-4F73-A50F-FC70368ED6AAQ34054746-207B49C9-31F1-4E63-90E0-2EDB3E2917B7Q34104748-E7F6E487-1A86-472F-9BBD-762D26B53B7BQ34335236-F8C35AA0-C143-4907-8D79-6DCCE66D3967Q35040008-C5048939-A315-442D-9A32-1474F10C9E19Q35121425-42A606DE-BAEB-47F2-8314-94267BB265BEQ35967453-C48C85A7-B02B-45AB-9C65-201A96AA7B9AQ36066956-CD937752-B393-4594-85B8-9801FA50AD11Q36271648-6A8EBBDF-58FC-4DB4-B062-1B2D82FE7379Q36343547-97C5DB96-3690-498A-94F4-AE858746C699Q36626518-921239D3-636A-4892-BD6E-A820CC013494Q37588637-5C1DDBA3-0AF2-455E-9E07-4285B3D5F568Q37653647-4948DB79-71BD-44F0-9436-E52A422AD10BQ37827345-9E912751-5CE4-4399-975C-00DAAB66F8C5Q37875765-D04F83D6-DC0E-4B50-8323-8B0E84D4CD20Q38586680-0E8CEA6A-598F-4D8F-A246-447858C2DBC7Q38767464-25CB5D85-E425-4E65-9E0B-8FE21994901CQ39011327-D48D54C7-AD0F-4743-8F36-CB080A4F24E5Q39338332-5A729E91-214A-4C21-A129-FA79410956C4Q39478158-3F28ABB2-12CC-49E5-90A3-E2B70A79E4BEQ39652840-3CB3D9DD-96DC-4607-8AF3-18405A1D65E4Q40045666-7871746F-002E-4646-A6D4-FA93D4149D04Q40103625-7242F93A-2D5E-4C58-B6C7-36C0490E1E20Q40164914-3E93E718-126B-4D6A-9CB2-D2CD62D12B33Q40409386-ED654B9F-BAFA-44A7-AD07-B5675619B5F6Q40909805-CBEFA9AA-8A6B-4DD7-B29D-78B8494EA68DQ42074628-AF5F8D14-D9BA-4155-931D-72DBB22DA39CQ42612968-4D4ADE0B-DAE3-4DD7-95E5-945B88A6BEFDQ42954068-64157A59-239D-4E4B-8269-88A3FB5207DFQ45221761-5A284471-C122-4FCE-BCCA-4A4C08610E09Q46576615-B41DA927-DA0C-4364-B80F-777632C76994
P2860
Echinocandins and pneumocandins--a new antifungal class with a novel mode of action
description
1997 nî lūn-bûn
@nan
1997 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Echinocandins and pneumocandins--a new antifungal class with a novel mode of action
@ast
Echinocandins and pneumocandins--a new antifungal class with a novel mode of action
@en
Echinocandins and pneumocandins--a new antifungal class with a novel mode of action
@nl
type
label
Echinocandins and pneumocandins--a new antifungal class with a novel mode of action
@ast
Echinocandins and pneumocandins--a new antifungal class with a novel mode of action
@en
Echinocandins and pneumocandins--a new antifungal class with a novel mode of action
@nl
prefLabel
Echinocandins and pneumocandins--a new antifungal class with a novel mode of action
@ast
Echinocandins and pneumocandins--a new antifungal class with a novel mode of action
@en
Echinocandins and pneumocandins--a new antifungal class with a novel mode of action
@nl
P356
P1476
Echinocandins and pneumocandins--a new antifungal class with a novel mode of action
@en
P2093
D W Denning
P356
10.1093/JAC/40.5.611
P407
P577
1997-11-01T00:00:00Z